Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Veru Inc. (NASDAQ: VERU) has reached full enrollment of over 150 patients for its Phase 2b QUALITY clinical study of enobosarm in combination with semaglutide (Wegovy®) for obesity. The study aims to evaluate enobosarm's efficacy in preserving muscle mass and enhancing fat loss in patients using GLP-1 drugs for weight management. Topline data for the primary endpoint of lean body mass is expected in January 2025.
Financial highlights for Q3 FY2024 include:
- Net revenues increased to $4.0 million from $3.3 million
- Gross profit increased to $1.3 million from $1.2 million
- Research and development expenses decreased to $4.9 million from $8.8 million
- Net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share
Veru Inc. (NASDAQ: VERU) ha raggiunto l'arruolamento completo di oltre 150 pazienti per il suo studio clinico di Fase 2b chiamato QUALITY, che utilizza enobosarm in combinazione con semaglutide (Wegovy®) per il trattamento dell'obesità. Lo studio ha l'obiettivo di valutare l'efficacia di enobosarm nel preservare la massa muscolare e migliorare la perdita di grasso nei pazienti che utilizzano farmaci GLP-1 per la gestione del peso. I dati principali per l'obiettivo primario della massa corporea magra sono attesi per gennaio 2025.
I risultati finanziari per il terzo trimestre dell'anno fiscale 2024 includono:
- Le entrate nette sono aumentate a $4,0 milioni rispetto a $3,3 milioni
- Il profitto lordo è aumentato a $1,3 milioni rispetto a $1,2 milioni
- Le spese per ricerca e sviluppo sono diminuite a $4,9 milioni rispetto a $8,8 milioni
- La perdita netta è stata di $11,0 milioni, ovvero $0,07 per azione, rispetto a $12,5 milioni, ovvero $0,14 per azione
Veru Inc. (NASDAQ: VERU) ha alcanzado la inscripción completa de más de 150 pacientes para su estudio clínico de Fase 2b llamado QUALITY, que combina enobosarm con semaglutide (Wegovy®) para la obesidad. El estudio tiene como objetivo evaluar la eficacia de enobosarm en la preservación de la masa muscular y la mejora de la pérdida de grasa en pacientes que utilizan medicamentos GLP-1 para el manejo del peso. Los datos principales para el objetivo primario de masa corporal magra se esperan en enero de 2025.
Los aspectos financieros del tercer trimestre del año fiscal 2024 incluyen:
- Los ingresos netos aumentaron a $4,0 millones desde $3,3 millones
- La ganancia bruta aumentó a $1,3 millones desde $1,2 millones
- Los gastos en investigación y desarrollo disminuyeron a $4,9 millones desde $8,8 millones
- La pérdida neta fue de $11,0 millones, o $0,07 por acción, en comparación con $12,5 millones, o $0,14 por acción
Veru Inc. (NASDAQ: VERU)는 비만 치료를 위한 enobosarm과 semaglutide (Wegovy®) 조합에 대한 Phase 2b QUALITY 임상 연구에서 150명 이상의 환자 등록을 완료했습니다. 이 연구의 목적은 체중 관리를 위해 GLP-1 약물을 사용하는 환자에서 enobosarm의 근육량 유지 및 지방 손실 향상 효과를 평가하는 것입니다. 제1차 지표인 근육량에 대한 주요 데이터는 2025년 1월에 발표될 예정입니다.
2024 회계연도 3분기 재무 하이라이트는 다음과 같습니다:
- 순수익은 $4.0백만에서 $3.3백만으로 증가했습니다
- 총 이익은 $1.3백만에서 $1.2백만으로 증가했습니다
- 연구 및 개발 비용은 $8.8백만에서 $4.9백만으로 감소했습니다
- 순손실은 $11.0백만, 주당 $0.07로, 이전의 $12.5백만, 주당 $0.14와 비교됩니다
Veru Inc. (NASDAQ: VERU) a atteint l'inscriptions complète de plus de 150 patients pour son étude clinique de Phase 2b QUALITY, utilisant l'enobosarm en combinaison avec le semaglutide (Wegovy®) pour traiter l'obésité. L'étude vise à évaluer l'efficacité de l'enobosarm dans la préservation de la masse musculaire et l'amélioration de la perte de graisse chez les patients utilisant des médicaments GLP-1 pour la gestion du poids. Les données clés pour l'objectif principal de la masse corporelle maigre sont attendues en janvier 2025.
Les points forts financiers pour le troisième trimestre de l'exercice fiscal 2024 incluent :
- Les revenus nets ont augmenté à 4,0 millions de dollars, contre 3,3 millions de dollars
- Le bénéfice brut a augmenté à 1,3 million de dollars, contre 1,2 million de dollars
- Les dépenses de recherche et développement ont diminué à 4,9 millions de dollars, contre 8,8 millions de dollars
- La perte nette était de 11,0 millions de dollars, soit 0,07 $ par action, contre 12,5 millions de dollars, soit 0,14 $ par action
Veru Inc. (NASDAQ: VERU) hat die vollständige Einschreibung von über 150 Patienten für die Phase 2b QUALITY-Studie zu enobosarm in Kombination mit semaglutide (Wegovy®) zur Bekämpfung von Übergewicht erreicht. Ziel der Studie ist es, die Wirksamkeit von enobosarm bei der Erhaltung der Muskelmasse und der Verbesserung des Fettabbaus bei Patienten, die GLP-1-Medikamente zur Gewichtsreduktion verwenden, zu bewerten. Die Hauptdaten für den primären Endpunkt der fettfreien Körpermasse werden im Januar 2025 erwartet.
Finanzielle Highlights für das 3. Quartal des Geschäftsjahres 2024 umfassen:
- Die Nettoumsätze stiegen auf 4,0 Millionen USD von 3,3 Millionen USD
- Der Bruttogewinn erhöhte sich auf 1,3 Millionen USD von 1,2 Millionen USD
- Die Forschungs- und Entwicklungskosten sanken auf 4,9 Millionen USD von 8,8 Millionen USD
- Der Nettoverlust betrug 11,0 Millionen USD oder 0,07 USD pro Aktie, verglichen mit 12,5 Millionen USD oder 0,14 USD pro Aktie
- Full enrollment reached for Phase 2b QUALITY clinical study, with topline data expected in January 2025
- Net revenues increased to $4.0 million from $3.3 million in Q3 FY2024
- Gross profit increased to $1.3 million from $1.2 million in Q3 FY2024
- Research and development expenses decreased to $4.9 million from $8.8 million in Q3 FY2024
- Operating loss decreased to $10.9 million from $13.7 million in Q3 FY2024
- Cash and cash equivalents increased to $29.2 million as of June 30, 2024, from $9.6 million as of September 30, 2023
- Year-to-date net revenues decreased to $10.2 million from $12.4 million
- Year-to-date gross profit decreased to $3.2 million from $6.0 million
- Year-to-date net loss was $29.3 million, or $0.22 per share, compared to $85.0 million, or $1.02 per share
- Net accounts receivable decreased to $1.6 million as of June 30, 2024, from $4.5 million as of September 30, 2023
Insights
The completion of enrollment for Veru's Phase 2b QUALITY study is a significant milestone in the development of enobosarm for obesity treatment. With >150 patients enrolled, the study aims to evaluate enobosarm's efficacy in preserving muscle mass while enhancing fat loss when combined with semaglutide (Wegovy®).
Key points to consider:
- Primary endpoint: total lean body mass
- Secondary endpoints: total body fat mass and physical function
- Topline data expected in January 2025
- Extension study to evaluate enobosarm's ability to maintain muscle and prevent weight regain after GLP-1 RA discontinuation
This study addresses a critical unmet need in obesity treatment, as muscle loss is a common side effect of GLP-1 RAs. If successful, enobosarm could potentially become a valuable adjunct therapy, improving the quality of weight loss for patients using GLP-1 RAs.
Veru's Q3 FY2024 financial results show a mixed picture. While there are some improvements, the company continues to operate at a loss:
- Revenue increased to
$4.0 million from$3.3 million year-over-year - Operating loss decreased to
$10.9 million from$13.7 million - Net loss per share improved to
$0.07 from$0.14
However, year-to-date figures show a decline in revenue and gross profit compared to the previous year. The company's cash position has improved to
Veru's focus on addressing muscle loss in obesity treatment positions it in a potentially lucrative niche within the booming GLP-1 RA market. Key market considerations include:
- The global obesity treatment market is projected to reach
$54 billion by 2030 - GLP-1 RAs like Wegovy® are driving significant growth in this sector
- Muscle loss is a recognized side effect of GLP-1 RAs, creating a demand for complementary therapies
If enobosarm demonstrates efficacy in the QUALITY study, it could capture a significant portion of patients using GLP-1 RAs. The extension study, evaluating enobosarm's ability to maintain benefits after GLP-1 RA discontinuation, could further expand its market potential. However, success hinges on positive clinical results and subsequent regulatory approval, which are still uncertain at this stage.
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients--
--Topline data for primary endpoint of lean body mass expected January 2025--
--Company presented enobosarm for high quality weight loss at the American Diabetes Association Meeting, the American Association of Clinical Endocrinology Annual Meeting, Biomed Israel 2024, and the GLP-1 Based Therapeutics Summit--
--Company to host conference call and webcast today at 8:00 a.m. ET--
MIAMI, FL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today provided a business update including progress on its Phase 2b QUALITY clinical trial and announced financial results for its fiscal 2024 third quarter.
"We are very pleased to have expeditiously reached our targeted full enrollment of greater than 150 patients for our enobosarm Phase 2b QUALITY clinical trial for muscle preservation for high quality weight loss in patients on treatment with a GLP-1 receptor agonist," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc. “I am most appreciative for all the great work done to complete enrollment by our clinical sites, our investigators, the Veru clinical operations team, and the full Veru team. Having reached this important milestone, we now anticipate topline data in January 2025."
"There is a substantial unmet medical need for a drug that can effectively preserve muscle mass while enhancing fat loss in patients using GLP-1 drugs for weight management," said Dr. Steiner. "Over the past quarter, we presented data at numerous prestigious scientific conferences and meetings, highlighting enobosarm's benefits in muscle preservation, physical function improvement, and safety as demonstrated in 5 previous enobosarm muscle clinical trials. We are enthusiastic about enobosarm's potential to address the muscle loss and physical function challenges in our Phase 2b QUALITY clinical trial.”
QUALITY Study - High Quality Weight Loss Program Update:
The Company’s Enobosarm Phase 2b QUALITY Clinical Trial
The Phase 2b, multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial is designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to preserve muscle and augment fat loss in approximately 150 patients with sarcopenic obesity or overweight elderly (>60 years of age) patients receiving semaglutide (Wegovy®). The primary endpoint is total lean body mass, and the key secondary endpoints are total body fat mass and physical function as measured by stair climb test at 16 weeks.
After completing the efficacy dose-finding portion of the Phase 2b clinical trial, it is expected that participants will then continue in blinded fashion into a Phase 2b extension clinical trial where all patients will stop receiving a GLP-1 RA, but will continue taking placebo, enobosarm 3mg, or enobosarm 6mg for an additional 12 weeks. The Phase 2b extension clinical trial will evaluate whether enobosarm can maintain muscle and prevent the fat and weight gain that occurs after discontinuing a GLP-1 RA.
The clinical study is being conducted in 14 clinical sites in the United States. Full patient enrollment has been reached for the approximately 150 patients in the Phase 2b QUALITY study. The Company now anticipates that the last patient to complete the Phase 2b QUALITY study will be in December 2024 with top line clinical results for the Phase 2b QUALITY clinical trial expected in January 2025. Furthermore, the topline results for the separate blinded Phase 2b extension clinical study may now be expected in the second calendar quarter of 2025.
Third Quarter Financial Summary: Fiscal 2024 vs Fiscal 2023
- Net revenues increased to
$4.0 million from$3.3 million - Gross profit increased to
$1.3 million from$1.2 million - Research and development expenses decreased to
$4.9 million from$8.8 million , as restated - Selling, general and administrative expenses decreased to
$7.5 million from$10.9 million - Operating loss decreased to
$10.9 million versus$13.7 million , as restated - Net loss was
$11.0 million , or$0.07 per share, compared to$12.5 million , or$0.14 per share, as restated
Year-to-Date Financial Summary: Fiscal 2024 vs Fiscal 2023
- Net revenues decreased to
$10.2 million from$12.4 million . Net revenues in the prior fiscal year included$3.9 million in sales to The Pill Club, for which we recorded a provision for credit losses in the prior year due to their bankruptcy. - Gross profit decreased to
$3.2 million from$6.0 million - Research and development expenses decreased to
$9.5 million from$47.3 million , as restated - Selling, general and administrative expenses decreased to
$23.4 million from$41.3 million - Operating loss was
$28.7 million versus$85.6 million , as restated - Net loss was
$29.3 million , or$0.22 per share, compared to$85.0 million , or$1.02 per share, as restated
Balance Sheet Information
- Cash and cash equivalents were
$29.2 million as of June 30, 2024 versus$9.6 million as of September 30, 2023 - Net accounts receivable were
$1.6 million as of June 30, 2024 versus$4.5 million as of September 30, 2023
Event Details
The audio webcast will be accessible under the Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 2561276, for one week.
About Sarcopenic Obesity
According to the CDC,
About Enobosarm
Enobosarm (aka ostarine, MK-2866, GTx-024, and VERU-024), a novel oral daily selective androgen receptor modulator (SARM), has been previously studied in 5 clinical studies involving 968 older normal men and postmenopausal women as well as older patients who have muscle wasting because of advanced cancer. Advanced cancer causes the loss of appetite where there is significant unintentional loss or wasting of both muscle and fat mass which is similar to what is observed with in patients taking GLP-1 RA drugs. We believe the totality of the clinical data from these previous five clinical trials demonstrates that enobosarm treatment leads to dose-dependent increases in muscle mass with improvements in physical function as well as significant dose-dependent reductions in fat mass. The patient data that were generated from these five enobosarm clinical trials in both elderly patients and in patients with a cancer induced appetite suppression provide strong clinical rationale for enobosarm. The expectation is that enobosarm in combination with a GLP-1 RA would potentially augment the fat reduction and total weight loss while preserving muscle mass.
Importantly, enobosarm has a large safety database, which includes 27 clinical trials involving 1581 men and women, some of which included patients dosed for up to 3 years. In this large safety database, enobosarm was generally well tolerated with no increases in gastrointestinal side effects. This is important as there are already significant and frequent gastrointestinal side effects with a GLP-1 RA treatment alone.
About Veru Inc.
Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin.
Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting.
Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to undertake further development of sabizabulin for the treatment of viral-induced ARDS until we obtain funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.
The Company also has an FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to whether and when the phase 2b trial of enobosarm discussed above will produce topline data or patients will progress into the extension study, the planned design, number of sites, timing, endpoints, patient population and patient size of such trial and whether such trial will successfully meet any of its endpoints, whether enobosarm will enhance weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will enhance weight loss and whether the Company will be successful in its transformation into a late stage biopharmaceutical company focused on obesity and oncology. The words "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: the development of the Company’s product portfolio and the results of clinical studies possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical studies and the ability to enroll subjects in accordance with planned schedules; the ability to fund planned clinical development as well as other operations of the Company; the timing of any submission to the FDA or any other regulatory authority and any determinations made by the FDA or any other regulatory authority; the Company’s existing product, FC2, and any future products, if approved, possibly not being commercially successful; the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; ; the Company’s failure to timely file certain reports in February 2024 may impair its ability to raise capital under the Company’s current effective shelf registration statement on Form S-3 or under a new registration statement; demand for, market acceptance of, and competition against any of the Company’s products or product candidates; new or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions; changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes; risks relating to the Company's development of its own dedicated direct to patient telehealth platform, including the Company's lack of experience in developing such a platform, potential regulatory complexity, development costs, and market awareness and acceptance of any telehealth platform we develop; risks relating to our ability to increase sales of FC2 after significant declines in recent periods due to telehealth industry consolidation and the bankruptcy of a large telehealth customer; the Company’s ability to protect and enforce its intellectual property; the potential that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; the concentration of accounts receivable with our largest customers and the collection of those receivables; the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, product testing, transportation delays or regulatory actions; costs and other effects of litigation, including product liability claims and securities litigation; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed from time to time in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2023, as amended by the Form 10-K/A, and subsequent quarterly reports on Form 10-Q. These documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors.
* Wegovy® is a registered trademark of Novo Nordisk A/S
FINANCIAL SCHEDULES FOLLOW
| Veru Inc. Condensed Consolidated Balance Sheets (unaudited) | ||||||||
| June 30, | September 30, | |||||||
| 2024 | 2023 (Restated) | |||||||
| Cash and cash equivalents | $ | 29,150,879 | $ | 9,625,494 | ||||
| Accounts receivable, net | 1,642,063 | 4,506,508 | ||||||
| Inventories, net | 4,942,246 | 6,697,117 | ||||||
| Prepaid expenses and other current assets | 2,740,953 | 2,104,103 | ||||||
| Total current assets | 38,476,141 | 22,933,222 | ||||||
| Plant and equipment, net | 1,491,129 | 1,652,732 | ||||||
| Operating lease right-of-use assets | 3,756,812 | 4,332,473 | ||||||
| Deferred income taxes | 12,479,488 | 12,707,419 | ||||||
| Goodwill | 6,878,932 | 6,878,932 | ||||||
| Other assets | 1,549,152 | 1,518,313 | ||||||
| Total assets | $ | 64,631,654 | $ | 50,023,091 | ||||
| Accounts payable | $ | 3,018,334 | $ | 12,931,172 | ||||
| Accrued compensation | 3,385,464 | 990,609 | ||||||
| Accrued expenses and other current liabilities | 3,229,849 | 3,024,328 | ||||||
| Residual royalty agreement liability, short-term portion | 986,388 | 864,623 | ||||||
| Total current liabilities | 10,620,035 | 17,810,732 | ||||||
| Residual royalty agreement liability, long-term portion | 8,577,067 | 8,870,136 | ||||||
| Operating lease liability, long-term portion | 3,074,721 | 3,634,114 | ||||||
| Other liabilities | 4,739,375 | 29,948 | ||||||
| Total liabilities | 27,011,198 | 30,344,930 | ||||||
| Total stockholders' equity | 37,620,456 | 19,678,161 | ||||||
| Total liabilities and stockholders' equity | $ | 64,631,654 | $ | 50,023,091 | ||||
| Veru Inc. Condensed Consolidated Statements of Operations (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2024 | 2023 (Restated) | 2024 | 2023 (Restated) | |||||||||||||
| Net revenues | $ | 3,953,870 | $ | 3,341,185 | $ | 10,229,897 | $ | 12,434,946 | ||||||||
| Cost of sales | 2,615,855 | 2,110,567 | 7,063,131 | 6,410,198 | ||||||||||||
| Gross profit | 1,338,015 | 1,230,618 | 3,166,766 | 6,024,748 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 4,879,024 | 8,787,636 | 9,515,865 | 47,259,464 | ||||||||||||
| Selling, general and administrative | 7,507,609 | 10,902,916 | 23,389,380 | 41,283,275 | ||||||||||||
| Provision for credit losses | — | — | — | 3,911,714 | ||||||||||||
| Impairment of intangible assets | — | — | — | 3,900,000 | ||||||||||||
| Total operating expenses | 12,386,633 | 19,690,552 | 32,905,245 | 96,354,453 | ||||||||||||
| Gain on sale of ENTADFI® assets | 110,000 | 4,723,623 | 1,028,372 | 4,723,623 | ||||||||||||
| Operating loss | (10,938,618 | ) | (13,736,311 | ) | (28,710,107 | ) | (85,606,082 | ) | ||||||||
| Non-operating income (expenses) | 132,166 | 1,271,216 | (288,711 | ) | 508,219 | |||||||||||
| Loss before income taxes | (10,806,452 | ) | (12,465,095 | ) | (28,998,818 | ) | (85,097,863 | ) | ||||||||
| Income tax expense (benefit) | 162,422 | 57,551 | 271,985 | (77,286 | ) | |||||||||||
| Net loss | $ | (10,968,874 | ) | $ | (12,522,646 | ) | $ | (29,270,803 | ) | $ | (85,020,577 | ) | ||||
| Net loss per basic and diluted common shares outstanding | $ | (0.07 | ) | $ | (0.14 | ) | $ | (0.22 | ) | $ | (1.02 | ) | ||||
| Basic and diluted weighted average common shares outstanding | 146,383,169 | 88,266,152 | 131,010,713 | 83,218,748 | ||||||||||||
| Veru Inc. Condensed Consolidated Statements of Cash Flows (unaudited) | ||||||||
| Nine Months Ended | ||||||||
| June 30, | ||||||||
| 2024 | 2023 (Restated) | |||||||
| Net loss | $ | (29,270,803 | ) | $ | (85,020,577 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | 12,177,598 | 16,573,752 | ||||||
| Changes in operating assets and liabilities | (223,034 | ) | (10,074,529 | ) | ||||
| Net cash used in operating activities | (17,316,239 | ) | (78,521,354 | ) | ||||
| Net cash provided by investing activities | 14,714 | 5,547,174 | ||||||
| Net cash provided by financing activities | 36,826,910 | 8,996,641 | ||||||
| Net increase (decrease) in cash | 19,525,385 | (63,977,539 | ) | |||||
| Cash at beginning of period | 9,625,494 | 80,190,675 | ||||||
| Cash at end of period | $ | 29,150,879 | $ | 16,213,136 | ||||
Investor and Media Contact:
Samuel Fisch
Executive Director, Investor Relations and Corporate Communications
Email: veruinvestor@verupharma.com
FAQ
What is the primary endpoint of Veru's Phase 2b QUALITY clinical study for enobosarm?
When does Veru expect to report topline data for the Phase 2b QUALITY clinical trial of enobosarm?
What was Veru's (VERU) net revenue for Q3 fiscal 2024?
How much cash and cash equivalents did Veru (VERU) have as of June 30, 2024?
What is the purpose of Veru's (VERU) enobosarm in the QUALITY clinical study?
